IDEAYA Receives Fast Track Designation for Potential First in Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1 2 Mutations
Tuesday, September 26, 2023 1 min read
Key Takeaway: IDEAYA Receives Fast Track Designation for Potential First in Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1 2 Mutations
Full Press Release Details
IDEAYA Receives Fast Track Designation for Potential First in Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1 2 Mutations.